Angiotensin II for the Treatment of COVID-19-Related Vasodilatory Shock
Date
2020Journal
Anesthesia and analgesiaPublisher
Wolters Kluwer HealthType
Article
Metadata
Show full item recordIdentifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083229742&doi=10.1213%2fANE.0000000000004825&partnerID=40&md5=60da3068b9b6ed5494b5e9da3651f4e5; http://hdl.handle.net/10713/12641ae974a485f413a2113503eed53cd6c53
10.1213/ANE.0000000000004825
Scopus Count
Related articles
- Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series.
- Authors: Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R, COVID-BioB Study Group.
- Issue date: 2020 May 15
- Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.
- Authors: Bobeck KA, Holtzclaw AW, Brown TE, Clark PA
- Issue date: 2020 Apr
- Haemodynamic monitoring and management in COVID-19 intensive care patients: an International survey.
- Authors: Michard F, Malbrain ML, Martin GS, Fumeaux T, Lobo S, Gonzalez F, Pinho-Oliveira V, Constantin JM
- Issue date: 2020 Oct
- Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.
- Authors: Wu Z, Hu R, Zhang C, Ren W, Yu A, Zhou X
- Issue date: 2020 Jun 5
- Impaired microcirculation function in COVID-19 and implications for potential therapies.
- Authors: Gąsecka A, Filipiak KJ, Jaguszewski MJ
- Issue date: 2020